Related Experiment Video
Updated: Jul 3, 2026
11:02
Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp1
Published on: May 27, 2016
Pharmacogenomic importance of ABCG2
George Cusatis1, Alex Sparreboom
1Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Pharmacogenomics
|August 7, 2008
Summary
Common genetic variations in the ABCG2 transporter influence drug absorption and response. These ABCG2 gene changes significantly impact how individuals process medications, affecting treatment outcomes.
Area of Science:
- Pharmacogenomics
- Molecular Biology
- Drug Metabolism
Background:
- The ATP-binding cassette transporter ABCG2 (also known as BCRP, MXR, and ABCP) is a crucial protein involved in drug transport.
- ABCG2 is highly expressed in the gastrointestinal tract and liver, playing a key role in the absorption, distribution, and excretion of numerous drugs.
- Interindividual variability in drug response is a significant challenge in clinical practice.
Purpose of the Study:
- To investigate the impact of common germline polymorphisms in the ABCG2 gene on transporter function.
- To understand how ABCG2 genetic variations contribute to variability in drug disposition and treatment outcomes.
Main Methods:
- Analysis of common germline polymorphisms within the ABCG2 gene.
- Assessment of the effects of these polymorphisms on ABCG2 expression and cellular localization.
- Evaluation of alterations in substrate recognition by the ABCG2 transporter due to genetic variations.
Main Results:
- Common germline polymorphisms in the ABCG2 gene were identified.
- These genetic variations were shown to affect ABCG2 expression, cellular localization, and/or substrate recognition.
- Altered ABCG2 transporter function significantly contributes to interindividual differences in drug disposition.
Conclusions:
- Germline polymorphisms in the ABCG2 gene are a major source of variability in the response to ABCG2 substrate drugs.
- Understanding these genetic factors is essential for predicting and optimizing drug therapy in patients.
- The impact of ABCG2 variations is substrate-dependent, highlighting the complexity of drug transport.
Related Concept Videos
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...